Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy

$267m Deal Expands Biotech’s Research

 
• By Andrew McConaghie

Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.

Brain scan
After starting with liver diseases, MiNA will now look to target neurodegenerative diseases

More from Business

More from Scrip